First-quarter license revenues increase 5 percent to $6.

At March 31, 2010, the company had cash and cash equivalents of $4.7 million as compared to $5.4 million at December 31, 2009. Long-term debt was also decreased by $1.5 million through the first quarter, which included a $1.0 million payment before the mandatory repayment schedule.. A.D.A.M. First-quarter license revenues increase 5 percent to $6.5 million A.D.A.M., Inc. , a leading provider of health benefit and information technology solutions, announced its financial outcomes for the first quarter ended March 31 today, 2010.5 million, up 5 percent over the first quarter of 2009.Wright. PharmAthene is an ideal partner for the advancement of MDX-1303 because of the commitment to the development of quality biodefense products, knowledge of the national government procurement procedure and proximity to U.S. Authorities and congressional decision manufacturers, said Donald L. Drakeman, President and CEO of Medarex. MDX-1303 is a human being antibody designed to drive back inhalation anthrax fully, the most lethal type of illness in human beings due to the Bacillus anthracis bacterium. The investigational antibody targets a proteins component of lethal toxins produced by the bacterium known as the anthrax protective antigen. The anthrax protecting antigen initiates the onset of the illness by attaching to cells in the infected person, and facilitates the access of additional destructive poisons in to the cells then.